계명대학교 의학도서관 Repository

A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg

Metadata Downloads
Author(s)
Cheol Whan LeeSang-Hong BaekTaek-Jong HongYoung-Jin ChoiYoung-Jo KimTae-Hoon AhnSang-Hyun IhmJang-Ho BaeSoon-Jun HongDoo-Il KimYoung-Keun AhnSeung-Ho HurDae-Gyun ParkDong-Ju ChoiSeung-Uk LeeBum-Soo KimKyu-Hyung RyuYang-Soo JangSang-Hoon LeeKi-Bae SeungHyo-Soo Kim
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cardiovascular Drugs and Therapy
Issued Date
2010
Volume
24
Issue
2
Abstract
Background

This study was designed to evaluate the safety and efficacy of algorithm-based atorvastatin therapy initiated at different starting doses of 10, 20, and 40 mg in Korean dyslipidemic patients.


Methods

Five hundred seventy-four patients were screened, and 425 were enrolled (low risk, n = 29; intermediate risk, n = 45; high risk, n = 351). The starting dose depended on a patient’s cardiovascular risk and LDL-cholesterol (LDL-C) levels.


Results

Of the patients, 253 (59.5%), 63 (14.8%) and 109 (25.6%) patients were assigned at baseline to 10 mg, 20 mg and 40 mg atorvastatin, respectively. 390 patients (91.8%) completed the study, and 35 discontinued prematurely. No patient in the low or intermediate risk groups was titrated to 80 mg at Week 4, whereas, 26 in the high risk group were. 81.9% of patients achieved their LDL-C target at Week 4, which was sustained through to Week 8 (86.0%). 89.1% of patients who were not titrated achieved their LDL-C target at Week 8, and 82.1% of patients who were titrated 1 step up achieved their LDL-C target at Week 8. Overall, about 40% reduction in LDL-C, non-HDL-C levels, and LDL-C/HDL-C ratio was observed during the follow-up. Triglyceride was reduced by ∼10% by Week 8. HDL cholesterol was slightly increased over 8 weeks (2.6%). Atorvastatin was well tolerated at all dose levels.


Conclusions

Patient-tailored statin therapy according to an individual’s risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients.


Key words
Atorvastatin – Dyslipidemia – Target goal achievement – Flexible-starting dose
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Cheol Whan Lee et al. (2010). A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg. Cardiovascular Drugs and Therapy, 24(2), 181–188. doi: 10.1007/s10557-010-6225-0
Type
Article
ISSN
0920-3206
Source
http://lps3.dx.doi.org.proxy.dsmc.or.kr/10.1007/s10557-010-6225-0
DOI
10.1007/s10557-010-6225-0
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35362
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.